Researchers use machine learning to predict adverse events during stem cell therapy for multiple myeloma, improving outpatient safety.
Key Details
- 1Researchers analyzed data from 109 multiple myeloma patients undergoing stem cell mobilization.
- 2Machine learning models identified time periods with low risk for serious side effects during therapy.
- 3Models could accurately predict the timing and occurrence of certain side effects in individual patients.
- 4Enables more patients to safely undergo chemotherapy and stem cell mobilization as outpatients.
- 5Outpatient treatment improves quality of life and allows for better hospital resource management.
- 6Findings published in npj Digital Medicine by Göttingen and Bielefeld researchers.
Why It Matters
By accurately stratifying patient risk using AI, more multiple myeloma patients could receive therapy outside the hospital, reducing healthcare costs and improving patient experience. This study highlights the growing role for AI in personalizing oncology care pathways.
Source
EurekAlert
Related News
•EurekAlert
FDA Approves Johns Hopkins AI Tool for Early Sepsis Detection
FDA clears an AI-driven system developed by Johns Hopkins to detect sepsis up to 48 hours earlier and reduce mortality rates.
•EurekAlert
New AI Vision-Language Model Enhances Chest CT Diagnostics
Researchers developed an interpretable AI model that uses visual question answering to generate detailed diagnostic findings from chest CT scans, aimed at improving lung cancer diagnosis.
•EurekAlert
Optical AI Chip Boosts Real-Time Dry Eye Gland Diagnosis Accuracy
A new metasurface spectral AI chip enables rapid, accurate diagnosis of meibomian gland dysfunction (MGD) from tissue samples, achieving 96.22% accuracy.